找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Ciprofloxacin i.v.; Defining Its Role in Christopher Garrard (Intensive Care Director) Conference proceedings 1994 Springer-Verlag Berlin H

[复制链接]
楼主: GERM
发表于 2025-3-25 07:22:13 | 显示全部楼层
发表于 2025-3-25 09:48:41 | 显示全部楼层
发表于 2025-3-25 12:24:04 | 显示全部楼层
发表于 2025-3-25 19:22:44 | 显示全部楼层
发表于 2025-3-25 21:08:08 | 显示全部楼层
发表于 2025-3-26 02:37:44 | 显示全部楼层
发表于 2025-3-26 05:38:18 | 显示全部楼层
发表于 2025-3-26 09:23:39 | 显示全部楼层
Efficacy and Safety of Ciprofloxacin in Various Intravenous Dosages,fections. The German Federal Health Office had specified 750 mg b.i.d. as the maximum dose for oral administration. We found it difficult to understand why, since its bioavailability is approx. 70%–80%; the maximum daily dose of ciprofloxacin for intravenous administration should be limited to 200 m
发表于 2025-3-26 14:24:27 | 显示全部楼层
Intravenous Ciprofloxacin Versus Imipenem/ Cilastatin in the Treatment of Severe Pneumonia,acquired infections and is the most common nosocomial infection encountered by patients in the intensive care unit (ICU), especially in patients requiring mechanical ventilatory support [1]. Nosocomial pneumonia in ventilated patients—referred to by the recently introduced term ventilator-associated
发表于 2025-3-26 17:38:06 | 显示全部楼层
,Conversion from Intravenous to Oral Ciprofloxacin: Observing the “Like-to-Like” Phenomenon,ften occurring late in the course of therapy. Because of cost-containment pressures the concept of switching to oral agents early in the course of antibiotic therapy is important, and this has become a major goal of antibiotic monitoring programs [1–10]. In several of these programs [1, 6, 8] partic
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-25 03:49
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表